| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ahmed M Abdel-Khale. A general factor of death distress in seven clinical and non-clinical groups. Death studies. vol 28. issue 9. 2004-10-28. PMID:15493083. |
the arabic scale of death anxiety (asda), the death depression scale (dds), and the death obsession scale (dos) were administered, individually, to 7 groups (n = 765) of egyptian normal participants (non-clinical), anxiety disorder patients, patients suffering from schizophrenia (males and females), and addicts (males only). |
2004-10-28 |
2023-08-12 |
human |
| Mei-Chun Hsiao, Cheng-Cheng Hsiao, Chia-Yih Li. Premenstrual symptoms and premenstrual exacerbation in patients with psychiatric disorders. Psychiatry and clinical neurosciences. vol 58. issue 2. 2004-07-19. PMID:15009825. |
premenstrual exacerbation was defined as premenstrual worsening of pre-existing generalized anxiety disorder (gad), major depressive disorder or dysthymic disorder (depressive disorders, dd), panic disorder (pd), or schizophrenia (sch). |
2004-07-19 |
2023-08-12 |
human |
| R Alexander Bantick, Eugenii A Rabiner, Ella Hirani, Michiel H de Vries, Susan P Hume, Paul M Grasb. Occupancy of agonist drugs at the 5-HT1A receptor. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 29. issue 5. 2004-05-25. PMID:14985704. |
drugs acting on the 5-ht1a receptor are used in the treatment of depression, generalized anxiety disorder, and schizophrenia. |
2004-05-25 |
2023-08-12 |
human |
| M Giuseppina Pisu, Mariangela Serr. Neurosteroids and neuroactive drugs in mental disorders. Life sciences. vol 74. issue 26. 2004-05-20. PMID:15094320. |
clinical and preclinical studies have suggested that fluctuations in the peripheral and brain concentrations of progesterone and deoxycorticosterone and its metabolites 3alpha,5alpha-tetrahydroprogesterone and 3alpha,5alpha-tetrahydrodeoxycorticosterone, respectively, might play an important role in certain pathological conditions characterized by emotional or affective disturbances, including major depression, anxiety disorders, and schizophrenia. |
2004-05-20 |
2023-08-12 |
Not clear |
| Tobias Bast, Joram Feldo. Hippocampal modulation of sensorimotor processes. Progress in neurobiology. vol 70. issue 4. 2003-11-26. PMID:12963091. |
moreover, hippocampal dysfunction has been implicated in neuropsychiatric diseases, such as schizophrenia and anxiety disorders, primarily characterized by non-mnemonic deficits in the processing of and responding to sensory information. |
2003-11-26 |
2023-08-12 |
human |
| Neil A Rector, Aaron T Bec. A clinical review of cognitive therapy for schizophrenia. Current psychiatry reports. vol 4. issue 4. 2002-10-09. PMID:12126597. |
understanding the aspects of schizophrenia in cognitive terms provides a framework for psychotherapeutic intervention with the adaptation of the cognitive strategies proven effective in the treatment of mood and anxiety disorders. |
2002-10-09 |
2023-08-12 |
Not clear |
| Ahmed M Abdel-Khale. Death obsession in Egyptian samples: differences among people with anxiety disorders, schizophrenia, addictions, and normals. Death studies. vol 26. issue 5. 2002-06-14. PMID:12046617. |
females have higher mean dos scores than their male counterparts in the normal, anxiety disorder patients, and patients suffering from schizophrenia groups |
2002-06-14 |
2023-08-12 |
human |
| L Dixon, L Green-Paden, J Delahanty, A Lucksted, L Postrado, J Hal. Variables associated with disparities in treatment of patients with schizophrenia and comorbid mood and anxiety disorders. Psychiatric services (Washington, D.C.). vol 52. issue 9. 2001-10-18. PMID:11533396. |
variables associated with disparities in treatment of patients with schizophrenia and comorbid mood and anxiety disorders. |
2001-10-18 |
2023-08-12 |
human |
| L Dixon, L Green-Paden, J Delahanty, A Lucksted, L Postrado, J Hal. Variables associated with disparities in treatment of patients with schizophrenia and comorbid mood and anxiety disorders. Psychiatric services (Washington, D.C.). vol 52. issue 9. 2001-10-18. PMID:11533396. |
the study compared self-reported comorbid affective and anxiety disorder diagnoses and treatments of african-american and caucasian subjects in a large sample of patients who had a diagnosis of schizophrenia. |
2001-10-18 |
2023-08-12 |
human |
| S Priebe, F Röhrich. Specific body image pathology in acute schizophrenia. Psychiatry research. vol 101. issue 3. 2001-07-05. PMID:11311932. |
cognitive (thoughts/beliefs regarding the body--body concept), affective (body satisfaction--body cathexis) and perceptual (body size estimation--body schema) facets of body image and psychopathology were assessed in in-patients with paranoid schizophrenia (n = 60), schizoaffective disorder (n = 19), depressive disorder (n = 40) and anxiety disorder (n = 28) at admission, and after 2 and 4 weeks of treatment. |
2001-07-05 |
2023-08-12 |
human |
| B K Christensen, R M Bilde. Dual cytoarchitectonic trends: an evolutionary model of frontal lobe functioning and its application to psychopathology. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 45. issue 3. 2000-05-17. PMID:10779881. |
to introduce and discuss an evolutionary model of frontal lobe functioning (the dual cytoarchitectonic trends theory [dtt]) and its application to understanding the neurobiology of schizophrenia and anxiety disorders. |
2000-05-17 |
2023-08-12 |
Not clear |
| H T Koivumaa-Honkanen, R Honkanen, R Antikainen, J Hintikka, H Viinamäk. Self-reported life satisfaction and treatment factors in patients with schizophrenia, major depression and anxiety disorder. Acta psychiatrica Scandinavica. vol 99. issue 5. 1999-07-20. PMID:10353454. |
our aim was to study the associations between life satisfaction and treatment factors and how depression affects these associations among patients with schizophrenia (n=403), major depression (n=349) and anxiety disorder (n=139) from a defined area. |
1999-07-20 |
2023-08-12 |
Not clear |
| C B Nemerof. Psychopharmacology of affective disorders in the 21st century. Biological psychiatry. vol 44. issue 7. 1999-01-06. PMID:9787875. |
data provided from such studies has served as the basis for the development of novel pharmacological approaches to the treatment of affective and anxiety disorders, as well as schizophrenia. |
1999-01-06 |
2023-08-12 |
Not clear |
| T E Smith, M T Shea, N R Schooler, H Levin, A Deutsch, E Grabstei. Personality traits in schizophrenia. Psychiatry. vol 58. issue 2. 1995-11-02. PMID:7568541. |
while many research efforts have described comorbidity in affective and anxiety disorders, less attention has been directed toward clarifying the relationships between stable and enduring character traits and axis i symptoms in schizophrenia. |
1995-11-02 |
2023-08-12 |
Not clear |
| C M Bank. Prophylactic potential of selective reuptake inhibitors in suicidal patients. International clinical psychopharmacology. vol 9 Suppl 4. 1995-08-31. PMID:7542677. |
the serotonergic dysfunction associated with suicidal behaviour is likely to be involved in other conditions such as depression, schizophrenia and anxiety disorder. |
1995-08-31 |
2023-08-12 |
Not clear |
| K S Kendler, D Wals. Schizotypal personality disorder in parents and the risk for schizophrenia in siblings. Schizophrenia bulletin. vol 21. issue 1. 1995-07-06. PMID:7770740. |
in siblings of probands with schizophrenia or schizophrenia spectrum, a parental diagnosis of spd significantly increased the risk for schizophrenia and schizophrenia spectrum disorders, but not for affective illness or anxiety disorders. |
1995-07-06 |
2023-08-12 |
Not clear |
| G F Busatto, L S Pilowsky, D C Costa, P J Ell, A Lingford-Hughes, R W Kerwi. In vivo imaging of GABAA receptors using sequential whole-volume iodine-123 iomazenil single-photon emission tomography. European journal of nuclear medicine. vol 22. issue 1. 1995-05-04. PMID:7698149. |
the protocol may be particularly useful in the investigation of neuropsychiatric conditions which are likely to involve more than one focus of gaba abnormalities, such as anxiety disorders and schizophrenia. |
1995-05-04 |
2023-08-12 |
human |
| K S Kendler, M McGuire, A M Gruenberg, A O'Hare, M Spellman, D Wals. The Roscommon Family Study. IV. Affective illness, anxiety disorders, and alcoholism in relatives. Archives of general psychiatry. vol 50. issue 12. 1993-12-30. PMID:8250681. |
this report seeks to evaluate the specificity of the familial liability to schizophrenia by examining in the relatives of the various proband groups the risk for affective illness (ai), anxiety disorders, and alcoholism. |
1993-12-30 |
2023-08-12 |
Not clear |
| C M Banki, L Karmacsi, G Bissette, C B Nemerof. Cerebrospinal-fluid neuropeptides: a biochemical subgrouping approach. Neuropsychobiology. vol 26. issue 1-2. 1993-02-01. PMID:1361969. |
cerebrospinal-fluid (csf) corticotropin-releasing hormone, somatostatin, and thyrotropin-releasing hormone were measured by specific radioimmunoassays in 257 hospitalized psychiatry patients suffering from dementia disorders (n = 85), schizophrenia (n = 104), and mood and anxiety disorders (n = 39). |
1993-02-01 |
2023-08-11 |
Not clear |
| P McDonald-Scott, S Machizawa, H Sato. Diagnostic disclosure: a tale in two cultures. Psychological medicine. vol 22. issue 1. 1992-06-04. PMID:1574550. |
while over 90% of both groups would inform patients with affective and anxiety disorders of their diagnoses, only 70% of north americans and less than 30% of japanese would similarly inform patients with schizophrenia or schizophreniform disorders. |
1992-06-04 |
2023-08-11 |
Not clear |